Although the improvement was greater with aflibercept than with the other two drugs ( P < 0.001 for aflibercept vs. bevacizumab and P = 0.03 for aflibercept vs. ranibizumab ) , it was not clinically meaningful , because the difference was driven by the eyes with worse visual acuity at baseline ( P < 0.001 for interaction ) .